



**Decision: PMPRB-09-D1-NEULASTA  
- Board Order**

**IN THE MATTER OF the *Patent Act* R.S.C. 1985, c. P-4,  
as amended**

**AND IN THE MATTER OF Amgen Canada Inc.  
(the "Respondent") and the medicine "Neulasta"**

**ORDER**

Pursuant to section 83 of the *Patent Act*, the Patented Medicine Prices Review Board (the "Board") issued a Notice of Hearing on March 16, 2009, pertaining to allegations of Board Staff that the medicine Neulasta had been, and was being, sold by Amgen Canada Inc. ("Amgen") in Canada at prices greater than the prices calculated in accordance with the Board's Guidelines. A pre-hearing conference has been held, and the matter has been set down for hearing.

On October 13, 2009, Amgen filed a Voluntary Compliance Undertaking ("VCU") by which Amgen proposed to resolve all issues raised in these proceedings.

The Board has decided to accept Amgen's VCU, effective as of the date of this Order. Accordingly, by Order of this Board the proceeding that was commenced by the issuance of the Notice of Hearing is hereby concluded.

Board Members: Dr. Brien G. Benoit  
Mary Catherine Lindberg  
Thomas (Tim) Armstrong

Board Counsel: Gordon Cameron

Sylvie Dupont  
Secretary of the Board

October 21, 2009